Kiniksa Pharmaceuticals International, plc $KNSA Shares Newly Bought by JW Asset Management LLC

JW Asset Management LLC acquired a new position in shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 22,000 shares of the company’s stock, valued at approximately $1,641,000. Kiniksa Pharmaceuticals International accounts for approximately 0.7% of JW Asset Management LLC’s holdings, making the stock its 15th largest holding.

A number of other hedge funds also recently bought and sold shares of KNSA. Allworth Financial LP lifted its stake in Kiniksa Pharmaceuticals International by 42.0% during the second quarter. Allworth Financial LP now owns 453 shares of the company’s stock valued at $29,000 after buying an additional 134 shares in the last quarter. Arizona State Retirement System increased its position in shares of Kiniksa Pharmaceuticals International by 2.1% in the second quarter. Arizona State Retirement System now owns 10,132 shares of the company’s stock worth $648,000 after acquiring an additional 209 shares in the last quarter. GAMMA Investing LLC increased its position in shares of Kiniksa Pharmaceuticals International by 21.1% in the third quarter. GAMMA Investing LLC now owns 1,278 shares of the company’s stock worth $95,000 after acquiring an additional 223 shares in the last quarter. Commonwealth Equity Services LLC increased its position in shares of Kiniksa Pharmaceuticals International by 2.2% in the third quarter. Commonwealth Equity Services LLC now owns 10,871 shares of the company’s stock worth $811,000 after acquiring an additional 237 shares in the last quarter. Finally, First Trust Advisors LP raised its holdings in shares of Kiniksa Pharmaceuticals International by 3.1% during the first quarter. First Trust Advisors LP now owns 9,876 shares of the company’s stock valued at $476,000 after acquiring an additional 293 shares during the period. 53.95% of the stock is owned by hedge funds and other institutional investors.

Kiniksa Pharmaceuticals International Trading Up 0.5%

Shares of NASDAQ KNSA opened at $96.28 on Friday. Kiniksa Pharmaceuticals International, plc has a one year low of $37.02 and a one year high of $99.31. The firm has a market capitalization of $7.56 billion, a PE ratio of 74.06 and a beta of 0.07. The business has a 50-day moving average price of $81.86 and a two-hundred day moving average price of $62.44.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last issued its earnings results on Tuesday, October 27th. The company reported $0.56 earnings per share for the quarter, beating analysts’ consensus estimates of $0.37 by $0.19. The company had revenue of $285.97 million for the quarter, compared to the consensus estimate of $260.66 million. Kiniksa Pharmaceuticals International had a return on equity of 17.27% and a net margin of 11.58%. Research analysts anticipate that Kiniksa Pharmaceuticals International, plc will post 1.30 EPS for the current year.

Insider Buying and Selling at Kiniksa Pharmaceuticals International

In other Kiniksa Pharmaceuticals International news, CEO Sanj K. Patel sold 151,300 shares of the company’s stock in a transaction that occurred on Wednesday, November 4th. The shares were sold at an average price of $94.71, for a total value of $14,329,623.00. Following the transaction, the chief executive officer owned 774,500 shares in the company, valued at approximately $73,352,895. This represents a 16.34% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Mark Ragosa sold 36,783 shares of the company’s stock in a transaction that occurred on Monday, November 2nd. The shares were sold at an average price of $92.16, for a total transaction of $3,389,921.28. Following the completion of the transaction, the chief financial officer owned 20,854 shares in the company, valued at approximately $1,921,904.64. This represents a 63.82% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 842,302 shares of company stock valued at $78,587,130 in the last 90 days. Corporate insiders own 51.98% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently commented on KNSA shares. Wells Fargo & Company upped their price target on shares of Kiniksa Pharmaceuticals International from $87.00 to $110.00 and gave the company an “overweight” rating in a research report on Wednesday, October 28th. Weiss Ratings lowered shares of Kiniksa Pharmaceuticals International from a “buy (b-)” rating to a “hold (c-)” rating in a research note on Wednesday, October 28th. Canaccord Genuity Group lifted their price objective on shares of Kiniksa Pharmaceuticals International from $64.00 to $98.00 and gave the stock a “buy” rating in a research report on Wednesday, July 29th. JPMorgan Chase & Co. boosted their target price on shares of Kiniksa Pharmaceuticals International from $107.00 to $122.00 and gave the company an “overweight” rating in a research note on Friday, October 30th. Finally, Wedbush increased their target price on Kiniksa Pharmaceuticals International from $99.00 to $102.00 and gave the company an “outperform” rating in a report on Wednesday, October 28th. Seven research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat.com, Kiniksa Pharmaceuticals International has a consensus rating of “Moderate Buy” and a consensus target price of $100.57.

Kiniksa Pharmaceuticals International Profile

Kiniksa Pharmaceuticals International plc is a biopharmaceutical company focused on developing and commercializing treatments for patients with autoimmune and inflammatory diseases. The company was established in 2015 and has operations in the United States and internationally. Kiniksa’s marketed medicine, Arcalyst (rilonacept), is approved in the United States to treat recurrent pericarditis and reduce the risk of recurrence in adults and certain pediatric patients. It is also approved for cryopyrin-associated periodic syndromes, a group of rare autoinflammatory conditions.